Alzinova AB (publ) (STO: ALZ)

Market Cap	329.91M
Revenue (ttm)	17.39M
Net Income (ttm)	-18.72M
Shares Out	89.17M
EPS (ttm)	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	264,336
Open	3.980
Previous Close	3.920
Day's Range	3.560 - 3.980
52-Week Range	0.949 - 4.620
Beta	1.31
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 14, 2024

About Alzinova AB

Alzinova AB (publ), a biopharmaceutical company, develops immunotherapies treatment for Alzheimer’s disease in Sweden. Its lead product candidate is ALZ-101, an active therapeutic oligomer-specific vaccine for the treatment of Alzheimer’s disease, which has completed part A of phase 1b study; and ALZ-201, a monoclonal antibody that neutralizes the toxic oligomers. The company is developing a humanized version of ALZ-201 in patients with Alzheimer’s disease that is in phase 1 clinical study. The company was incorporated in 2011 and is based in M...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Employees: 5
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: ALZ

Financial Performance

In 2023, Alzinova AB's revenue was 19.87 million, an increase of 19.49% compared to the previous year's 16.63 million. Losses were -16.48 million, 25.9% more than in 2022.